


## GSK837149A

Cat. No.:	HY-117769		
CAS No.:	13616-29-0		
Molecular Formula:	C <sub>23</sub> H <sub>22</sub> N <sub>8</sub> O <sub>5</sub> S <sub>2</sub>		
Molecular Weight:	554.6		
Target:	Fatty Acid Synthase (FASN)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

Description	GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (K <sub>i</sub> =30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	Ki: 30 nM (type I FASN) <sup>[1]</sup>
In Vitro	GSK837149A (0.1 nM-0.1 mM) shows an increasing inhibition effect on acetyl-CoA/malonyl-CoA, and acetoacetyl-CoA <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Vázquez MJ, et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction. FEBS J. 2008 Apr;275(7):1556-1567.

[2]. Singha PK, et al. Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells. Eur J Pharm Sci. 2020 Apr 7;149:105321.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA